Interview with Janssen’s Dr Amrit Ray: One Company’s Efforts To Bring Order To The Challenging Area of Compassionate Use

Where do you go? Who do you ask? What’s the policy? Compassionate use programs can be hard for patients to navigate. And for the companies who run them, they’re often very challenging to manage. Janssen is one company that is trying to introduce some order.

In 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between its pharma unit Janssen and the Division of Medical Ethics at the New York University (NYU) School of Medicine. The partnership involved the Compassionate Use Advisory Committee (CompAC), a panel of external bioethical experts, physicians and patient representatives convened by NYU, examining US-based requests for compassionate use of Janssen’s investigational drugs and making recommendations as to who would most benefit from such use. The project has been a success and could act as a model for other companies, says Janssen's Chief Medical Officer Dr Amrit Ray. However, as Ray explained to Sukaina Virji*, there is still much to learn in this area, and the initiative has not been without its ethical dilemmas along the way.

The Takeaways, Part One – Dr Amrit Ray on Janssen’s efforts to bring order to compassionate use
  • In compassionate use, historically, it's not been clear where to go, who to ask, how to ask, what the process and policies will be, and that's led to a lot of inconsistency for patients,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Base Benefit-Risk Decisions On Data, Not Opinion And Passion, CDER’s Tidmarsh Says

 
• By 

New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.

Pink Sheet Podcast: FDA’s New Top Drug Regulator, Sarepta’s Options After Elevidys Stand-Off

Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.